Carisma Therapeutics Inc [CARM] stock is trading at $0.50, up 0.94%. An important factor to consider is whether the stock is rising or falling in short-term value. The CARM shares have gain 14.65% over the last week, with a monthly amount glided 14.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Carisma Therapeutics Inc [NASDAQ: CARM] stock has seen the most recent analyst activity on December 12, 2024, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $1 from $10. Previously, BTIG Research downgraded its rating to Neutral on December 10, 2024. On April 11, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $6 on the stock. CapitalOne started tracking the stock assigning a Overweight rating and suggested a price target of $10 on October 03, 2023. Evercore ISI initiated its recommendation with a Outperform and recommended $12 as its price target on July 06, 2023. Jefferies upgraded its rating to Buy for this stock on May 31, 2023, and upped its price target to $7. In a note dated May 24, 2023, H.C. Wainwright initiated an Buy rating and provided a target price of $10 on this stock.
Carisma Therapeutics Inc [CARM] stock has fluctuated between $0.38 and $2.77 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Carisma Therapeutics Inc [NASDAQ: CARM] shares were valued at $0.50 at the most recent close of the market. An investor can expect a potential return of 1100.0% based on the average CARM price forecast.
Analyzing the CARM fundamentals
Carisma Therapeutics Inc [NASDAQ:CARM] reported sales of 20.27M for the trailing twelve months, which represents a drop of -11.55%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -3.29%, Pretax Profit Margin comes in at -3.16%, and Net Profit Margin reading is -3.15%. To continue investigating profitability, this company’s Return on Assets is posted at -1.52, Equity is -9.57 and Total Capital is -2.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4963 points at the first support level, and at 0.4878 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5116, and for the 2nd resistance point, it is at 0.5184.
Ratios To Look Out For
For context, Carisma Therapeutics Inc’s Current Ratio is 3.23. On the other hand, the Quick Ratio is 3.23, and the Cash Ratio is 2.55. Considering the valuation of this stock, the price to sales ratio is 1.04.
